SCHEMBL6869800

SCHEMBL6869800

O=C(NCc1cc(Cl)cc(Cl)c1)c1ccccc1-c1ccccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
HPGD P15428 3/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
TACR1 P25103 1/20 0.46
RAB9A P51151 1/20 0.45
METAP2 P50579 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
APEX1 P27695 2/20 0.43
HSP90AA1 P07900 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
NLRP3 Q96P20 1/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6871367 0.94 CHRNB2 (0.45) CHRNB2CHRNB4CHRNA3CHRNA4HPGD
SCHEMBL6862802 0.81 TACR1 (0.61) CHRNB2CHRNB4CHRNA3CHRNA4HPGD
SCHEMBL6867090 0.78 CHRNB2 (0.64) CHRNB2CHRNB4CHRNA3CHRNA4HPGD
SCHEMBL29941278 0.73 ERCC1 (0.59) HPGDKMT2AALDH1A1TACR1RAB9A
SCHEMBL8055115 0.71 HPGD (0.71) CHRNB2CHRNB4CHRNA3CHRNA4HPGD
SCHEMBL7828799 0.70 KMT2A (0.77) CHRNB2CHRNB4CHRNA3CHRNA4HPGD
SCHEMBL6869706 0.69 HPGD (0.59) HPGDTSHRKMT2AALDH1A1LMNA
SCHEMBL10107711 0.69 HPGD (0.56) HPGDTSHRKMT2AALDH1A1LMNA
SCHEMBL5643784 0.69 TSHR (0.60) HPGDTSHRKMT2AALDH1A1LMNA
SCHEMBL1500764 0.68 KMT2A (0.58) HPGDKMT2AALDH1A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171419-B1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
US-6552088-B2 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor HOFFMANN-LA ROCHE INC. 2003-04-22 US disclosed
US-20020040060-A1 Biphenyl derivatives BOS MICHAEL (CA) 2002-04-04 US disclosed
EP-1171419-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-01-16 EP disclosed
US-6291465-B1 Biphenyl derivatives HOFFMANN-LA ROCHE INC. 2001-09-18 US disclosed
WO-2000053572-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040060-A1 Biphenyl derivatives NR1H4, NR1H2, NR1H3 CHRNB2 1434/4885CHRNB4 1471/4885CHRNA3 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.